Obalon Therapeutics Inc. (Nasdaq: OBLN) terminated its public offering of more than 5.4 million common shares due to allegations of improper revenue recognition. The stock price plummeted $1.73 to close at $3.46.
Obalon Therapeutics cancels offering
January 23, 2018 at 16:47 PM EST
